Home Teva And AbCellera Enter Into Agreement To Discover Rare Monoclonal Antibodies
 

Keywords :   


Teva And AbCellera Enter Into Agreement To Discover Rare Monoclonal Antibodies

2016-02-26 02:15:58| drugdiscoveryonline News Articles

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies.

Tags: enter agreement discover rare

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11 (CFI-ZCT1J02)
27.11
27.11QUICKSILVER 8/S 130
27.11
27.11Laurene LaVallis Key To Our Love 7 US
27.11THE SCOPE AFTER DARK LP
27.11
27.11DVD
More »